ReviewInternational journal of nanomedicine2026
Design of Nanostructured Enzyme Immobilized Platforms for Precise Diagnosis and Treatment of Endocrine Disease: An Updated Review.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endocrine diseases are a big health problem worldwide, due to their complex pathophysiology, the diversity of clinical phenotypes and the necessity of sensitive, stable, and real‑time monitoring of hormonal and metabolic biomarkers. Conventional endocrine assays are plagued by the need for the presence of large amounts of biomarker, the time needed for the response, poor enzyme stability, matrix effects and lack of continuous or point of care suitability. To overcome these limitations, technical approaches are based on nanostructured enzyme-immobilized platforms that provide high surface to volume ratio for high enzyme loading, tunable surface chemistry for control of immobilization, enhanced electron-transfer pathways for electrochemical signal amplification, porous architecture to confine and stabilize enzyme, and plasmonic effects (eg, localized surface plasmon resonance) for optical signal enhancement. In this review, an updated overview of the design principles, mechanisms and biomedical relevance of enzyme immobilization on nanostructured platforms for the diagnosis and treatment-related management of endocrine diseases is provided. The carbon-based materials, metallic and metal-oxide nanoparticles, polymeric systems, metal-organic frameworks, covalent organic frameworks, and hybrid nanocomposites are discussed in the context of their role in tuning the loading of enzymes, catalytic activity, operational stability, signal transduction and biocompatibility. Particular emphasis is placed on applications in diabetes mellitus, thyroid, adrenal disorders and lipid metabolic imbalance, as well as emerging applications in targeted therapy, enzyme guided drug delivery, oxidative-stress regulation and nanotheranostics. The current problems of reproducibility, long-term stability, scalability, biocompatibility and clinical translation are critically discussed. Potential future trends, such as AI-powered biosensors, next-generation nanozymes, multiplexed platforms, and personalized nanomedicine strategies, are suggested.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.